JAMA Network
About The Study: Among people with insulin-naive type 2 diabetes, once-weekly icodec demonstrated superior HbA1c reduction to once-daily degludec after 26 weeks of treatment, with no difference in weight change and a higher rate of combined level two or three hypoglycemic events in the context of less than one event per patient-year exposure in both groups.
Authors: Ildiko Lingvay, M.D., of the University of Texas Southwestern Medical Center in Dallas, and Yiming Mu, M.D., of the Chinese People's Liberation Army General Hospital in Beijing, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.11313)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
